Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 26% ± 6% |
Insufficient scRNA-seq data for expression of TRIM11 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 1298.67 | 21 / 21 | 100% | 14.22 | 504 / 504 |
esophagus | 100% | 1379.40 | 1445 / 1445 | 100% | 12.38 | 183 / 183 |
lung | 100% | 1367.06 | 578 / 578 | 100% | 11.15 | 1155 / 1155 |
ovary | 100% | 1274.89 | 180 / 180 | 100% | 13.69 | 430 / 430 |
stomach | 100% | 1091.60 | 359 / 359 | 100% | 11.40 | 286 / 286 |
uterus | 100% | 1380.28 | 170 / 170 | 100% | 15.46 | 459 / 459 |
breast | 100% | 1252.67 | 459 / 459 | 100% | 14.24 | 1117 / 1118 |
intestine | 100% | 1352.68 | 966 / 966 | 100% | 12.44 | 526 / 527 |
prostate | 100% | 1817.15 | 245 / 245 | 100% | 11.55 | 501 / 502 |
skin | 100% | 1656.48 | 1809 / 1809 | 100% | 11.45 | 471 / 472 |
thymus | 100% | 1350.45 | 653 / 653 | 100% | 7.69 | 602 / 605 |
brain | 99% | 2486.21 | 2614 / 2642 | 100% | 7.24 | 704 / 705 |
pancreas | 98% | 758.95 | 323 / 328 | 99% | 11.32 | 177 / 178 |
adrenal gland | 100% | 1243.35 | 258 / 258 | 98% | 6.62 | 225 / 230 |
kidney | 100% | 1122.11 | 89 / 89 | 97% | 5.22 | 873 / 901 |
liver | 99% | 587.77 | 224 / 226 | 95% | 6.41 | 386 / 406 |
adipose | 100% | 1058.87 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 11.38 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 12.46 | 29 / 29 |
spleen | 100% | 2695.79 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 11.43 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 19.82 | 1 / 1 |
blood vessel | 100% | 940.23 | 1333 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1641.44 | 917 / 929 | 0% | 0 | 0 / 0 |
heart | 97% | 586.00 | 837 / 861 | 0% | 0 | 0 / 0 |
muscle | 63% | 257.76 | 507 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0010468 | Biological process | regulation of gene expression |
GO_0045087 | Biological process | innate immune response |
GO_0051865 | Biological process | protein autoubiquitination |
GO_0046598 | Biological process | positive regulation of viral entry into host cell |
GO_0050768 | Biological process | negative regulation of neurogenesis |
GO_0046597 | Biological process | negative regulation of viral entry into host cell |
GO_0044790 | Biological process | suppression of viral release by host |
GO_0140972 | Biological process | negative regulation of AIM2 inflammasome complex assembly |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0032897 | Biological process | negative regulation of viral transcription |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0030674 | Molecular function | protein-macromolecule adaptor activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TRIM11 |
Protein name | Tripartite motif containing 11 E3 ubiquitin-protein ligase TRIM11 (EC 2.3.2.27) (Protein BIA1) (RING finger protein 92) (Tripartite motif-containing protein 11) |
Synonyms | RNF92 |
Description | FUNCTION: E3 ubiquitin-protein ligase that promotes the degradation of insoluble ubiquitinated proteins, including insoluble PAX6, poly-Gln repeat expanded HTT and poly-Ala repeat expanded ARX (By similarity). Mediates PAX6 ubiquitination leading to proteasomal degradation, thereby modulating cortical neurogenesis (By similarity). May also inhibit PAX6 transcriptional activity, possibly in part by preventing the binding of PAX6 to its consensus sequences (By similarity). May contribute to the regulation of the intracellular level of HN (humanin) or HN-containing proteins through the proteasomal degradation pathway (By similarity). Mediates MED15 ubiquitination leading to proteasomal degradation . May contribute to the innate restriction of retroviruses . Upon overexpression, reduces HIV-1 and murine leukemia virus infectivity, by suppressing viral gene expression . Antiviral activity depends on a functional E3 ubiquitin-protein ligase domain . May regulate TRIM5 turnover via the proteasome pathway, thus counteracting the TRIM5-mediated cross-species restriction of retroviral infection at early stages of the retroviral life cycle . Acts as an inhibitor of the AIM2 inflammasome by promoting autophagy-dependent degradation of AIM2 . Mechanistically, undergoes autoubiquitination upon DNA stimulation, promoting interaction with AIM2 and SQSTM1/p62, leading to AIM2 recruitment to autophagosomes . . |
Accessions | ENST00000284551.11 [Q96F44-1] ENST00000366699.3 [Q96F44-2] R4GNB9 R4GMV1 ENST00000493030.6 Q96F44 ENST00000602308.1 ENST00000602582.5 R4GNC3 |